Wednesday, March 30, 2016 5:02:00 AM PDT | VentureDeal
Washington, DC -- Chase Pharmaceuticals has received nearly $12 million in new equity venture capital funding, according to an SEC regulatory filing.
Chase says that it is "engaged in the clinical development of medically improved treatments for central nervous system diseases." The company is in the middle of Phase 2 trials of its treatment candidate CPC-201 for patients with mild to moderate Alzheimer's disease. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of 14 investors participated in the offering. The company was founded by Chief Scientific Officer Thomas Chase.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
